Pluripotency without tumors?

Written byAlla Katsnelson

| 2 min read

Japanese researchers who linkurl:reprogrammed;http://www.the-scientist.com/blog/display/53873/ pluripotency into adult human skin cells say they have improved the technique, according to a linkurl:paper;http://www.nature.com/nbt published online today (Nov. 30) in Nature Biotechnology. linkurl:Shinya Yamanaka;http://www.frontier.kyoto-u.ac.jp/rc02/kyojuE.html of Kyoto University and his colleagues originally used four transcription factors to induce pluripotency in linkurl:mouse;http://www.the-scientist.com/blog/display/24307/ embryonic and adult fibroblast cells, and most recently, linkurl:adult human skin cells.;http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=18035408&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum But the process caused tumors in a significant percentage of the chimeric mice generated from the cells - a problem the researchers attributed to one of the four genes, c-Myc, which induces proliferation. In the current study, the researchers showed that pluripotent cells can be made from both mouse and human adult cells without introducing the c-Myc gene, by transducing just the other three. It's not that Myc isn't needed in the process, the authors noted in the paper; rather, they suggest that the other three genes may be spurring endogenous Myc activity. None of the 26 chimeras made from cells generated without c-Myc developed tumors within 100 days, compared to six out of 36 chimeras made from cells using all four genes. linkurl:James Thomson's;http://ink.primate.wisc.edu/~thomson/ group at the University of Wisconsin, Madison, also linkurl:reported;http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=18029452&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum reprogramming human cells last week, using a set of four transcription factors that did not include c-Myc. So far, though, they have used their approach in neonatal cells, but not adult cells. The Yamanaka group's study "suggests that tumour formation was indeed due to abnormal cMyc expression rather than some general problem of the reprogramming method," linkurl:Robin Lovell-Badge;http://www.nimr.mrc.ac.uk/devgen/lovell/ of the MRC National Institute for Medical Research in London, wrote in an Email to The Scientist. "However, they did not look thoroughly for tumours and screened relatively few animals, so more work is needed on this." So far, too, efficiency with this triple-gene method is much lower than with the original four genes; half of the experiments without c-Myc did not produce pluripotent cells at all, while experiments using the four genes almost always yielded pluripotent colonies. "Does this mean that it now only works with a rare cell type?" Lovell-Badge wrote. "As always, many more questions are posed than answered."

Pluripotency without tumors?

The Scientist ARCHIVES

Become a Member of

Meet the Author

Alla Katsnelson

Related Research Resources

A Stubborn Gene, a Failed Experiment, and a New Path

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies